NCT05237388View on ClinicalTrials.gov

Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease

PHASE2RecruitingINTERVENTIONAL

Enrollment

75

Participants

Timeline

Start Date

April 20, 2023

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Chronic Kidney Diseases

Interventions

DRUG

Baricitinib

One pill daily

DRUG

Placebo

Baricitinib placebo pill

Trial Locations (1)

27705

RECRUITING

Duke Research at Pickett Road, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Institute on Minority Health and Health Disparities (NIMHD)

NIH

collaborator

Eli Lilly and Company

INDUSTRY

lead

Duke University

OTHER

NCT05237388 - Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease | Biotech Hunter | Biotech Hunter